Cargando…

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals

BACKGROUND: The use of antiretroviral (ARV) dual therapy for treatment of HIV is increasing; raltegravir with boosted darunavir (bDRV) is recommended in certain clinical situations in DHHS guidelines. Dolutegravir (DTG) with bDRV has not been widely studied. We sought to determine the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hawkins, Kellie, Montague, Brian, Rowan, Sarah, Mclees, Margaret, Beum, Robert, Johnson, Steven C, Gardner, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252975/ http://dx.doi.org/10.1093/ofid/ofy209.151

Ejemplares similares

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
por: Jabłonowska, Elżbieta, et al.
Publicado: (2019)

548. Antiretroviral Therapy Regimen Characteristics Within an Urban, Safety-Net Clinic in the United States
por: Hawkins, Kellie, et al.
Publicado: (2018)

Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus
por: Lee, Sang-Ah, et al.
Publicado: (2018)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

ODP596 Central Adrenal Insufficiency After Intra-Articular Triamcinolone Injection In A Patient On Dolutegravir And Cobicistat Boosted Darunavir
por: Chen, Ying, et al.
Publicado: (2022)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009)

Robert Whytt [1714-1766]
Publicado: (1932)

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)
por: Pasquau, Juan, et al.
Publicado: (2019)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
por: Gubavu, Camelia, et al.
Publicado: (2016)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Thomas Charles Hope (1766-1844).
por: Cragg, R H
Publicado: (1967)

Domenique Jean Larrey, 1766-1842
por: Roberts, A. E. S.
Publicado: (1956)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

1406. A Systematic Quality Improvement Initiative to Improve Chagas Disease Screening in Patients with HIV at a Large Safety Net Clinic in Denver
por: Barahona, Lilian Vargas, et al.
Publicado: (2023)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

553. A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir
por: Verna, John, et al.
Publicado: (2018)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
por: Neely, Michael, et al.
Publicado: (2009)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

1766. Osimertinib-Associated Progressive Multifocal Leucoencephalopathy
por: Gilotra, Tarvinder S, et al.
Publicado: (2019)

2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2019)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
por: Bedimo, Roger J., et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

The genome sequence of the spectacle, Abrostola tripartita Hufnagel, 1766
por: Boyes, Douglas, et al.
Publicado: (2021)

The genome sequence of the Festoon, Apoda limacodes (Hufnagel, 1766)
por: Broad, Gavin R.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vuhmd7pjb5b8ln49fvadv9i719